BACKGROUND
When different strengths of agents are parity priced by manufacturers, that is the per unit cost is the same regardless of the strength, tablet splitting can be a means of reducing program costs while not limiting access. The Mississippi Division of Medicaid (MDOM) identified aripiprazole as a good candidate for a tablet splitting policy. The MDOM consulted with psychiatrists to assess the feasibility and to identify potential difficulties with a tablet splitting policy for aripiprazole. Potential issues identified that made programming for electronic prior authorization (EPA) difficult included labeling, OAs are sometimes required for tolerability reasons, and the daily dose computed from quantity dispensed and days supply on claims does not always result in a reasonable daily dose. MDOM implemented the aripiprazole tablet splitting criteria through EPA at the end of February 2013.

OBJECTIVES AND PURPOSE
The goal of a tablet splitting criteria is to reduce total program costs without restricting beneficiary access to treatment options. The research objectives were to evaluate the impact of a tablet splitting policy for aripiprazole on access to care and pharmacy costs.

METHODS
A retrospective analysis was conducted of the MDOM prescription claims for February 2013 – April 2014. All aripiprazole prescriptions were extracted and daily consumption (DACON) was computed by dividing the number of tablets dispensed by the days supply. Tablet splitting rates and the number of beneficiaries taking aripiprazole were computed for each month. Saving were computed based on the average cost of goods paid for each tablet strength and the number of tablets that would have been dispensed without tablet splitting for the period January – June 2014.

A base-line of rate of dispensing at 0.5 tabs/day or each strength was derived as the average during the 6 months prior to policy implementation. The average for the first 6 months in 2014 was used as an estimate of what will be achieved from this criteria.

CONCLUSIONS
When medications are not priced on a linear per milligram basis, tablet splitting can result in significant savings without reducing access to needed doses.

ACKNOWLEDGMENTS/DISCLOSURES
The work reported was conducted by the MS-DUR program in the Center for Pharmaceutical Marketing and Management as part of the retrospective drug use analysis activities conducted under contract with the Mississippi Division of Medicaid. The views expressed are those of the authors and do not necessarily reflect those of Mississippi Division of Medicaid or the University of Mississippi.